Study of BEBT-908 in Subjects With Advanced Hematological Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 2, 2016

Primary Completion Date

March 8, 2019

Study Completion Date

March 8, 2019

Conditions
Relapsed or Refractory Non-Hodgkin's LymphomaRelapsed or Refractory Multiple Myeloma
Interventions
DRUG

BEBT-908 for injection

"Dose escalation phase:10 or 15、22.5、33.75、45mg/m2, intravenous drip, firstly single dose, after the observation period, the drug was administered continuously for 1 cycle (21 days), 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week.~Dose expansion phase:15 or 22.5mg/m2,intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week,21 days as cycle."

Trial Locations (1)

410006

Hunan Cancer Hospital, Changsha

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeBetter Med Inc

INDUSTRY